Skip to main content
Go to homepage

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Description:

For complete information, please view the study on clinicaltrials.gov.

This study is being done in collaboration with Cincinnati Children's Hospital.

Interested in participating?
We are currently recruiting
Full IRB Study Title:
ADVL1513: A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
IRB Study ID:
1042403-1
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program